F-18 FDG PET in Detecting Renal Cell Carcinoma

References

• Ak I., Stokkel M., Pauwels E. Positron emission tomography with 2-(18F)fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumors. J Cancer Res Clin Oncol 2000; 126: 560–74 (Review)
   PubMed Web of Science ®Google Scholar
• Bachor R., Kotzerke J., Gottfried H., Brandle E., Reske S., Hautmann R. Positron emission tomography in diagnosis of renal cell carcinoma. Urology A 1996; 35: 146–50
   Google Scholar
• Boren E., Delbeke D., Ptton J., Sandler M. Comparison of FDG PET and positron coincidence detection imaging using a dual-head gamma camera with 5/8-inch NaI(Tl) crystals in patients with suspected body malignancies. Eur J Nucl Med 1999; 26: 379–87
   PubMedGoogle Scholar
• Chang C., Wu H., Tsai J., Shen Y., Changlai S., Kao A. Detecting metastasis pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int 2003; 70: 311–35
   PubMed Web of Science ®Google Scholar
• Goldberg M., Mayo-Smith W., Papanicolaou N., Fischman A., Lee M. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 1997; 52: 510–15
   PubMedGoogle Scholar
• Hain S., O'Doherty M., Timothy A., Leslie M., Harper P., Huddart R. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumors at relapse. Br J Cancer 2000; 83: 863–9
   PubMed Web of Science ®Google Scholar
• Hilton S. Imaging of renal cell carcinoma. Semin Oncol 2000; 27: 150–9
   PubMedGoogle Scholar
• Hofer C., Kubler H., Hartung R., Breul J., Avril N. Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol 2001; 40: 481–7
   PubMedGoogle Scholar
• Hofer C., Laubenbacher C., Block T., Breul J., Hartung R., Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36: 31–5
   Web of Science ®Google Scholar
• Jadvar H., Kherbache H., Pinski J., Conti P. Diagnostic role of (F-18)-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol 2003; 60: 395–400
   PubMed Web of Science ®Google Scholar
• Jemal A., Tiwari R., Murray T., Ghafoor A., Samuels A., Ward E., et al. American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8–29
   PubMed Web of Science ®Google Scholar
• Kang D., White RL J., Zuger J., Sasser H., Teigland C. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. Urol 2004; 171: 1806–9
   Google Scholar
• Kostakoglu L., Coleman M., Leonard J., Kuji I., Zoe H., Goldsmith S. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43: 1018–27
   PubMed Web of Science ®Google Scholar
• Lam J., Shvarts O., Pantuck A. Changing concepts in the surgical management of renal cell carcinoma. Eur Urol 2004; 45: 692–705
   PubMedGoogle Scholar
• Lanctin H., Futter N. Renal cell carcinoma: incidental detection. Can J Surg 1992; 33: 488–90
   Google Scholar
• Majhail N., Urbain J., Albani J., Kanvinde M., Rice T., Novick A., et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003; 21: 3995–4000
   PubMed Web of Science ®Google Scholar
• Mevorach R., Segal A., Tesegno M., Frank I. Renal cell carcinoma: incidental diagnosis and natural history: review of 235 cases. Urology 1992; 39: 519–22
   PubMed Web of Science ®Google Scholar
• Miller E., Lerman H., Gutman M., Figer A., Livshitz G., Even-Sapir E. The clinical impact of camera-based positron emission tomography imaging in patients with recurrent colorectal cancer. Invest Radiol 2004; 39: 8–12
   PubMedGoogle Scholar
• Montravers F., Grahek D., Kerrou K., Younsi N., Doublet J., Gattegno B., et al. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera. J Nucl Med 2000; 41: 78–84
   PubMed Web of Science ®Google Scholar
• Motzer R. Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma. Crit Rev Oncol Hematol 2003; 27: S33–9
   Google Scholar
• Oyama N., Akino H., Suzuk i. Y., Kanamaru H., Ishida H., Tanase K., et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 2001; 22: 963–9
   PubMed Web of Science ®Google Scholar
• Pantuck A., Zisman A., Belldegrun A. The changing natural history of renal cell carcinoma. J Urol 2001; 166: 1611–23
   PubMed Web of Science ®Google Scholar
• Shreve P., Steventon R., Deters E., Kison P., Gross M., Wahl R. Oncologic diagnosis with 2-(fluorine-18)fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology 1998; 207: 431–7
   PubMedGoogle Scholar
• Spermon J., De Geus-Oei L., Kiemeney L., Witjes J., Oyen W. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int 2002; 89: 549–56
   PubMed Web of Science ®Google Scholar
• Stokkel M., Terhaard C., Mertens I., Hordijk G., van Rijk P. Fluorine-18-FDG detection of laryngeal cancer postradiotherapy using dual-head coincidence imaging. J Nucl Med 1998; 39: 1385–87
   PubMedGoogle Scholar
• Tatsumi M., Yutani K., Watanabe Y., Myoshi S., Tomiyama N., Johkoh T., et al. Feasibility of fluorodeoxyglucose dualhead gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET. J Nucl Med 1999; 40: 566–73
   PubMedGoogle Scholar
• Walter C., Scheidhauer K., Scharl A., Goering U., Theissen P., Kugel H., et al. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions. Eur Radiol 2003; 13: 1651–6
   PubMedGoogle Scholar